TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have successfully completed either T-GD04-082 (NCT00251745) or T-GD04-083 (NCT00251758) or have a diagnosis of gastroesophageal reflux disease with or without erosive esophagitis.~Exclusion Criteria:~* Any condition that may require inpatient surgery during the course of the study.~* Use of prescription or non-prescription proton pump inhibitors, histamine (H2) receptor antagonists, sucralfate, misoprostol or prokinetics throughout the study.~* Use of antacids \[except for study supplied Gelusil®\].~* Subjects using drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose for 4 weeks prior to dosing and throughout the study.~* Evidence of uncontrolled systemic disease.~* Allergy to any proton pump inhibitor including Prilosec, Nexium, Prevacid, or others, any component of dexlansoprazole MR, or Gelusil/antacid.~* Need to take blood thinners.~* Need to take more than 12 doses of non-steroidal anti-inflammatory drugs per month.~* Had cancer (except basal cell cancer of the skin) within 3 years prior to screening.~* Has other esophageal disease including Barrett's esophagus or strictures requiring dilation.~* Has had radiation or cryotherapy to the esophagus.~* Has active gastric or duodenal ulcers within 4 weeks of starting study drug.~* Has a history of hypersecretory conditions such as Zollinger Ellison Syndrome.~* History of alcohol abuse.~* Has acquired immunodeficiency syndrome.~* Has had acute upper gastrointestinal bleeding within 4 weeks of endoscopy.~* Received a blood product transfusion within 3 months of taking the first dose of study drug.~* Has previously participated in another dexlansoprazole MR long-term treatment clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 90 mg QD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE AND ECG MORPHOLOGY OF EUGLYCEMICS:A CLINICAL STUDY

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers having age from 20- 40 years~* Non-Diabetic~* Non-Alcoholics~* Non-Smokers~* Non-Hypertensive~Exclusion Criteria:~* Patients with QT interval prolongation in ECG~* Patients unwilling to give consent~* Patients already on antibiotic therapy for a period one to two week or above.~* Patients who are on other drugs that induces or decreases drug metabolism of quinolones.~* Pregnant female patients.~* Abuse of alcoholic beverages~* Participants who are Allergic or Hypersensitivity to the said drug~* Participants who have participated in a clinical trial within 3 months before the study period.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Moxfloxacin Group (Type: EXPERIMENTAL): In this arm 30 healthy volunteers were selected and they were given Moxifloxacin drug.
- Gemifloxacin Group (Type: EXPERIMENTAL): In this arm 30 healthy volunteers were selected and they were given Gemifloxacin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Paracetamol or Dexamethasone for Post-spinal Anesthesia Shivering

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • on 300 patients aged 18-60 years~  * of the American Society of Anesthesiologists (ASA) physical status I or II~ * underwent non-obstetric surgeries under spinal anesthesia. A written informed consent was obtained from all patients to participate in the study.~Exclusion Criteria:~* • Patient's refusal,~  * duration of surgery more than 120 min,~ * obesity with body mass index (BMI) \>35 kg/m2,~ * generalized infection or localized infection at level of blockade,~ * neurologic disease,~ * coagulation disorder,~ * patients with hypo- or hyperthyroidism,~ * cardiopulmonary disease,~ * psychological disorders,~ * a need for blood transfusion during surgery,~ * an initial body temperature \>38.0C or \<36.0C,~ * a known history of alcohol or substance abuse,~ * or receiving vasodilators, or medications likely to alter thermoregulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- P (Paracetamol) group:(n=100) (Type: ACTIVE_COMPARATOR): None
- D (Dexamethasone) (Dex) group: (n=100) (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Homozygous for the F508del mutation or heterozygous for F508del and a minimal function (MF) mutation (F/F or F/MF genotypes)~Key Exclusion Criteria:~* Clinically significant cirrhosis with or without portal hypertension~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* Solid organ or hematological transplantation~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Part A: ELX/TEZ/IVA (Type: EXPERIMENTAL): Participants weighing greater than or equal to (\>=)14 kilograms (kg) at screening received elexacaftor (ELX) 100 milligrams (mg) once daily (qd)/tezacaftor (TEZ) 50 mg qd/ivacaftor (IVA) 75 mg every 12 hours (q12h) in the treatment period for 15 days.
- Part B: ELX/TEZ/IVA (Type: EXPERIMENTAL): Participants weighing (\>=)14 kg at screening received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h. Participants weighing (\>=)10 kg to less than (\<)14 kg received ELX 80 mg qd/TEZ 40 mg qd/IVA 60 mg once every morning (qAM) and 59.5 mg once every evening (qPM) in the treatment period for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mucinex® for Treatment of Filamentary Keratitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with filamentary keratitis~* 18 years and older~Exclusion Criteria:~* Active ocular surface infection of any type~* Recent ocular surgery (\<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones~* Schirmer's test\<3mm~* History of hypersensitivity to Mucinex®~* Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Mucinex (Type: OTHER): 600 mg of Mucinex 2 times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed aggressive \[de novo or transformed\] NHL according to REAL/WHO classification.~* At least one objectively measurable lesion as demonstrated by CT, spiral CT, or MRI and plain radiograph of the chest (chest x-ray, for chest lesions only) that can be followed for response as target lesion.~* Relapse after 2 or more prior regimens of chemotherapy~* ECOG performance status of 0, 1, or 2~* Adequate hematologic, renal and hepatic function~* LVEF ≥50% determined by MUGA scan~Exclusion Criteria:~* Prior treatment with a cumulative dose of doxorubicin or equivalent exceeding 450 mg/m²~* Prior allogenic stem cell transplant~* Histological diagnosis of Burkitt lymphoma, lymphoblastic lymphoma or Mantle cell lymphoma~* Active CNS lymphoma or HIV-related lymphoma.~* Any chemotherapy, radiotherapy, or other anticancer treatment (including corticosteroid, 10 or more mg/day of prednisone or equivalent) within the 2 weeks before randomization~* Pregnant women or nursing mothers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): Pixantrone (BBR2778)
- Comparator Arm (Type: ACTIVE_COMPARATOR): To be chosen by the investigator, among vinorelbine, oxaliplatin, ifosfamide, etoposide or mitoxantrone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female child at least 6 months of age and under 6 years of age (has not yet reached 72 months of age) at the enrollment visit.~* Free of obvious health problems, as established by the medical history and screening evaluations, including physical examination.~* Subject's parent or legal guardian is willing to provide written informed consent prior to the subject's first study vaccination.~Exclusion Criteria:~* Known hypersensitivity to any component in adjTIV or TIV (which include egg protein) or placebo.~* Receipt of any non-study vaccine within two weeks prior to enrollment or refusal to postpone receipt of such vaccines until after the Day 56 visit.~* Previous receipt of any influenza vaccine.~* Hypersensitivity after previous administration of any vaccine.~* Acute illness accompanied by a body temperature of 37.5°C or greater (axillary measurement) within 14 days of enrollment visit. (Enrollment and administration of adjTIV, TIV, or placebo should be postponed until at least 14 days after recovery. Minor illnesses, such as mild upper respiratory infection, with an axillary temperature of \<37.5°C, are not reason for exclusion or postponing study vaccination.)~* Any condition that, in the opinion of the investigator, would pose a health risk to the participant if he/she participates in the study or would interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 71 Months
- Healthy Volunteers: t

Study Arms:
- adjTIV (Type: EXPERIMENTAL): Children randomized to receive adjTIV
- TIV (Type: EXPERIMENTAL): Children randomized to receive TIV
- Placebo (Type: PLACEBO_COMPARATOR): Children randomized to receive Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hypovolemic shock admitted to the emergency room or ICU with systolic blood pressure ≤ 90 mmHg at presentation and continue to receive standard shock treatment. Blood Lactate level indicative of hypovolemic shock (\>2.0 mmol/L).~Exclusion Criteria:~1. Development of any other terminal illness not associated with Hypovolemic shock during the 28-day observation period.~2. Patient with altered consciousness not due to Hypovolemic shock.~3. Known pregnancy.~4. Cardiopulmonary resuscitation (CPR) before randomization.~5. Presence of a do not resuscitate order.~6. Patient is participating in another interventional study.~7. Patients with systemic diseases which were already present before having trauma, such as: cancer, chronic renal failure, liver failure, decompensated heart failure or AIDS.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: ACTIVE_COMPARATOR): Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
- PMZ-2010 (centhaquine) (Type: EXPERIMENTAL): Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of essential thrombocythaemia with high-risk profile.~Exclusion Criteria:~* previous treatment with cytoreductive drugs or Anagrelide~* pregnant women or women in childbearing age with inadequate contraception~* patients with contraindications for study drugs due to anaphylactoid reactions to either active or non-active ingredients~* known lactose intolerance~* cardiovascular diseases grade III-IV (Toxicity Criteria of the South West Oncology Group, 1992) - with a negative benefit/risk ratio~* severe renal disease (Creatinin Clearance \< 30 ml/min)~* severe liver disease (AST or ALT \> 5-times normal)~* coexisting, malignant, systemic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Anagrelide (Type: EXPERIMENTAL): None
- Hydroxyurea (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Capsaicin Gel During Exercise Within the Heat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 19-45 years of age~* cleared for physical activity via the 2022 physical activity readiness questionnaire (PARQ)~* no self-reported adverse reactions to capsaicin~Exclusion Criteria:~* outside 19-45 years of age~* not cleared for physical activity via the 2022 physical activity readiness questionnaire (PARQ)~* self-report or signs of sensitivity to capsaicin~* pregnant~* breast feeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Capsaicin gel application (Type: EXPERIMENTAL): Capsaicin gel will be applied to the skin prior to exercise in the heat
- Hypoallergenic gel application (Type: PLACEBO_COMPARATOR): A hypoallergenic gel will be applied to the skin prior to exercise in the heat

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Eye treated with XEN 45 Gel Stent for primary open angle glaucoma as a standalone procedure or in combination with phacoemulsification~* XEN 45 Gel Stent was implanted between 1 January 2014 and 1 October 2015~Exclusion Criteria~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Implant (Type: None): Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
- Implant + Phaco (Type: None): Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NOURISH: Nourishing Our Understanding of Role Modeling to Improve Support and Health

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* To qualify for participation, parents/caregivers must have a child between the ages of 6 and 11 with a BMI \> the 85th percentile \[128\].~* This child must also primarily reside in the participating caregiver's home.~* Participants also need to speak English fluently, and be able to understand and follow basic instructions and perform simple exercises.~Exclusion Criteria:~* Caregivers are ineligible if they are:~  1. non-ambulatory,~ 2. pregnant,~ 3. or have a clinical diagnosis that may be negatively impacted by exercise.~* Parents whose children have a medical condition or developmental disorder that precludes weight loss using conventional diet and exercise methods are also ineligible for participation.~All parents meeting study criteria will be offered participation in the randomized trial comparing NOURISH with a control group.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NOURISH (Type: EXPERIMENTAL): The first 2 waves and second 2 waves of participants will receive a 12 and 6 week face-to-face intervention (NOURISH), respectively. The interventions differ only in duration. They cover the same concepts which are grounded in Social Cognitive Theory (SCT). Throughout the interventions the influence of social learning on behavioral outcomes (e.g., parent's modeling of healthy behavior) will be emphasized. Weekly topics provide information about implementing healthy lifestyle behaviors, authoritarian parenting approaches, and strategies for overcoming barriers to change. Parents will receive pedometers for themselves and 1 of their children. A one-hour booster session will be available for all intervention participants 2 months after completion of the interventions.
- Wellness Group (Type: PLACEBO_COMPARATOR): The placebo control group will attend a group session moderated by an independent interventionist. This interventionist will be blinded to the Specific Aims and hypotheses of this study. The session will address the role of diet and exercise in pediatric overweight. In addition, control parents will receive pedometers (and instructions on their use) for themselves and 1 of their children. Finally, control participants will be mailed publicly available brochures on pediatric overweight on 2 occasions during the study. Control participants will also be sent home one additional packet of information (essentially a review of previous mail outs) 2 months after post-testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Hyaluronidase and Dexametasone in Reduction of Postoperative Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* symmetrical mandibular wisdom teeth with bone retention~* patients who are signed informed consent and acceptance of study involvement forms~Exclusion Criteria:~* existence of any systemic disease~* existence of any periodical drug intake~* existence of difference in operation times of right and left impacted wisdom teeth extractions more than 5 minutes~* existence of pregnancy~* existence of breastfeeding

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- hyaluronidase (Type: EXPERIMENTAL): None
- hyaluronidase control (Type: NO_INTERVENTION): None
- dexamethasone (Type: EXPERIMENTAL): None
- dexamethasone control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete